1110-P: Use of IDegLira Is Associated with High Persistency Rates Up to 12 Months (M) and Improved A1C after 6M in Swedish Clinical Practice

Abstract

This retrospective study examines outcomes associated with use of IDegLira - a fixed-ratio insulin degludec/liraglutide combination - in a large real-world cohort of patients with type 2 diabetes in Sweden. Data were obtained from the Swedish National Diabetes Registry on patients who initiated IDegLira (index date) until the end of 2017 (or 30 June/1 January 2017 for 6M/12M for persistency analyses). Persistency at 6M was defined as ≥1 more IDegLira withdrawal within 6M of index date, and 12M persistency was ≥1 more withdrawal in M6-12. Clinical variables were assessed at baseline (closest measurement to index date in previous 12M) and 6M ± 45 days after IDegLira initiation. Mean daily IDegLira dose was calculated from volume withdrawn during defined time periods of ≥6M. Baseline characteristics for overall cohort (N=3000) are in Table. At 6 and 12M, 2281/2432 (94%) and 1482/1760 (84%) patients were persistent, respectively. In persistent patients, least squares mean [95% CI] change in A1C and body mass index was -0.9% [-1.0; -0.8] and -0.3 kg/m2 [-0.5; -0.2] at 6M, respectively and mean daily IDegLira dose was 32-35 U at all 180-day periods assessed (Table). After 6M, IDegLira use in Sweden is associated with improved A1C and no clinically significant change in BMI at a moderate mean daily insulin dose, and 84% were persistent at 12M. Disclosure B. Eliasson: Advisory Panel; Self; Amgen Inc., AstraZeneca, Merck Sharp & Dohme Corp. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH. Other Relationship; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. J. Ekelund: Employee; Spouse/Partner; AstraZeneca. Stock/Shareholder; Spouse/Partner; AstraZeneca. A. Svensson: None. M. Miftaraj: None. A. Mårdby: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J. da Rocha Fernandes: Employee; Self; Novo Nordisk A/S. Funding Novo Nordisk A/S